O-GlcNAcylation promotes migration and invasion in human ovarian cancer cells via the RhoA/ROCK/MLC pathway

Niu,Yichao; Xia,Ye; Wang,Jingyun; Shi,Xiaofei

doi:10.3892/mmr.2017.6244

O-GlcNAcylation promotes migration and invasion in human ovarian cancer cells via the RhoA/ROCK/MLC pathway

Authors:
- Yichao Niu
- Ye Xia
- Jingyun Wang
- Xiaofei Shi
View Affiliations

Affiliations: Department of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai 200126, P.R. China
Published online on: February 24, 2017 https://doi.org/10.3892/mmr.2017.6244
Pages: 2083-2089
Copyright: © Niu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

O-GlcNAcylation is a dynamic and reversible post-translational modification associated with the regulation of multiple cellular functions. The addition and removal of O‑Linked β-N-acetylglucosamine (O‑GlcNAc) on target proteins is catalyzed by O‑GlcNAc transferase (OGT) and O‑GlcNAcase (OGA), respectively. Accumulating evidence suggests that O-GlcNAcylation is associated with the malignancy of several types of human cancer. To investigate the effect of O-GlcNAcylation on ovarian cancer phenotypes, global O‑GlcNAc levels were decreased by OGT silencing through RNA interference and increased by inhibiting OGA activity with Thiamet‑G. Transwell assay results demonstrated that OGT silencing inhibited the migration and invasion of SKOV3 and 59M ovarian cells in vitro, while Thiamet‑G treatment promoted migration and invasion. Furthermore, a pull‑down assay and western blot analysis demonstrated that Thiamet-G treatment enhanced RhoA activity and the phosphorylation of the Rho‑associated protein kinase (ROCK) substrate, myosin light chain (MLC), while OGT silencing attenuated RhoA activity and MLC phosphorylation. In addition, RhoA silencing via RNA interference and inhibition of ROCK activity with Y‑27632 prevented Thiamet‑G‑induced increases in cell migration and invasion. These data suggest that O‑GlcNAcylation augments the motility of ovarian cancer cells via the RhoA/ROCK/MLC signaling pathway. Therefore, O‑GlcNAcylation may be a potential target for the diagnosis and treatment of ovarian cancer.

View Figures

View References

1	Torres CR and Hart GW: Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc. J Biol Chem. 259:3308–3317. 1984.PubMed/NCBI
2	Hart GW, Slawson C, Ramirez-Correa G and Lagerlof O: Cross talk between O-GlcNAcylation and phosphorylation: Roles in signaling, transcription, and chronic disease. Annu Rev Biochem. 80:825–858. 2011. View Article : Google Scholar : PubMed/NCBI
3	Hart GW, Housley MP and Slawson C: Cycling of O-linked β-N-acetylglucosamine on nucleocytoplasmic proteins. Nature. 446:1017–1022. 2007. View Article : Google Scholar : PubMed/NCBI
4	Wells L, Vosseller K and Hart GW: Glycosylation of nucleocytoplasmic proteins: Signal transduction and O-GlcNAc. Science. 291:2376–2378. 2001. View Article : Google Scholar : PubMed/NCBI
5	Hanover JA: Glycan-dependent signaling: O-linked N-acetylglucosamine. FASEB J. 15:1865–1876. 2001. View Article : Google Scholar : PubMed/NCBI
6	Lazarus BD, Love DC and Hanover JA: O-GlcNAc cycling: Implications for neurodegenerative disorders. Int J Biochem Cell Biol. 41:2134–2146. 2009. View Article : Google Scholar : PubMed/NCBI
7	Yang X, Ongusaha PP, Miles PD, Havstad JC, Zhang F, So WV, Kudlow JE, Michell RH, Olefsky JM, Field SJ and Evans RM: Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance. Nature. 451:964–969. 2008. View Article : Google Scholar : PubMed/NCBI
8	Slawson C and Hart GW: O-GlcNAc-signalling: Implications for cancer cell biology. Nat Rev Cancer. 11:678–684. 2011. View Article : Google Scholar : PubMed/NCBI
9	Zachara NE and Hart GW: Cell signaling, the essential role of O-GlcNAc. Biochim Biophys Acta. 1761:599–617. 2006. View Article : Google Scholar : PubMed/NCBI
10	Chou TY, Hart GW and Dang CV: C-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas. J Biol Chem. 270:18961–18965. 1995. View Article : Google Scholar : PubMed/NCBI
11	Kamemura K, Hayes BK, Comer FI and Hart GW: Dynamic interplay between O-glycosylation and O-phosphorylation of nucleocytoplasmic proteins. Alternative glycosylation/phosphorylation of Thr-58, a known mutational hot spot of c-Myc in lymphomas, is regulated by mitogens. J Biol Chem. 277:19229–19235. 2002. View Article : Google Scholar : PubMed/NCBI
12	Gu Y, Mi W, Ge Y, Liu H, Fan Q, Han C, Yang J, Han F, Lu X and Yu W: GlcNAcylation plays an essential role in breast cancer metastasis. Cancer Res. 70:6344–6351. 2010. View Article : Google Scholar : PubMed/NCBI
13	Mi W, Gu Y, Han C, Liu H, Fan Q, Zhang X, Cong Q and Yu W: O-GlcNAcylationis a novel regulator of lung and colon cancer malignancy. Biochim Biophys Acta. 1812:514–519. 2011. View Article : Google Scholar : PubMed/NCBI
14	Yehezkel G, Cohen L, Kliger A, Manor E and Khalaila I: O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) in primary and metastatic colorectal cancer clones and effect of N-acetyl-beta-D-glucosaminidase silencing on cell phenotype and transcriptome. J Biol Chem. 287:28755–28769. 2012. View Article : Google Scholar : PubMed/NCBI
15	Ma Z, Vocadlo DJ and Vosseller K: Hyper-OglcNAcylation is anti-apoptotic and maintains constitutive NF-κB activity in pancreatic cancer cells. J Biol Chem. 288:15121–15130. 2013. View Article : Google Scholar : PubMed/NCBI
16	Lynch TP, Ferrer CM, Jackson SR, Shahriari KS, Vosseller K and Reginato MJ: Critical role of O-Linked β-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. J Biol Chem. 287:11070–11081. 2012. View Article : Google Scholar : PubMed/NCBI
17	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: GLOBOCAN 2008v1.2. Cancer incidence, mortality and prevalence worldwideIARC Cancer Base No 10 [Internet]. Lyon, France: IARC Press; 2010
18	Treating advanced ovarian cancer. https://www.cancerresearchuk.orgMay 16–2015.
19	Ruddon RW: Cancer biology. 4th edition. Oxford University Press; Oxford: pp. 2232007
20	Basile JR, Gavard J and Gutkind JS: Plexin-B1 utilizes RhoA and Rho kinase to promote the integrin-dependent activation of Akt and ERK and endothelial cell motility. J Biol Chem. 282:34888–34895. 2007. View Article : Google Scholar : PubMed/NCBI
21	Nikonova E, Tsyganov MA, Kolch W, Fey D and Kholodenko BN: Control of the G-protein cascade dynamics by GDP dissociation inhibitors. Mol Biosyst. 9:2454–2462. 2013. View Article : Google Scholar : PubMed/NCBI
22	Samuel MS, Lopez JI, McGhee EJ, Daniel R, Croft DR, Strachan D, Timpson P, Munro J, Schröder E, Zhou J, et al: Actomyosin-mediated cellular tension drives increased tissue stiffness and β-catenin activation to induce epidermal hyper-plasia and tumor growth. Cancer Cell. 19:776–791. 2011. View Article : Google Scholar : PubMed/NCBI
23	Rösel D, Brábek J, Tolde O, Mierke CT, Zitterbart DP, Raupach C, Bicanová K, Kollmannsberger P, Panková D, Vesely P, et al: Up-regulation of Rho/ROCK signaling in sarcoma cells drives invasion and increased generation of protrusive forces. Mol Cancer Res. 6:1410–1420. 2008. View Article : Google Scholar : PubMed/NCBI
24	Gadea G, De Toledo M, Anguille C and Roux P: Loss of p53 promotes RhoA-ROCK-dependent cell migration and invasion in 3D matrices. J Cell Biol. 178:23–30. 2007. View Article : Google Scholar : PubMed/NCBI
25	Amano M, Ito M, Kimura K, Fukata Y, Chihara K, Nakano T, Matsuura Y and Kaibuchi K: Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem. 271:20246–20249. 1996. View Article : Google Scholar : PubMed/NCBI
26	Riento K and Ridley AJ: Rocks: Multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol. 4:446–456. 2003. View Article : Google Scholar : PubMed/NCBI
27	Kolodney MS and Elson EL: Contraction due to microtubule disruption is associated with increased phosphorylation of myosin regulatory light chain. Proc Natl Acad Sci USA. 92:10252–10256. 1995. View Article : Google Scholar : PubMed/NCBI
28	Kamai T, Tsujii T, Arai K, Takagi K, Asami H, Ito Y and Oshima H: Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res. 9:2632–2641. 2003.PubMed/NCBI
29	Pan Y, Bi F, Liu N, Xue Y, Yao X, Zheng Y and Fan D: Expression of seven main Rho family members in gastric carcinoma. Biochem Biophys Res Commun. 315:686–691. 2004. View Article : Google Scholar : PubMed/NCBI
30	Jiang WG, Watkins G, Lane J, Cunnick GH, Douglas-Jones A, Mokbel K and Mansel RE: Prognostic value of rho GTPases and rho guanine nucleotide dissociation inhibitors in human breast cancers. Clin Cancer Res. 9:6432–6440. 2003.PubMed/NCBI
31	Kamai T, Yamanishi T, Shirataki H, Takagi K, Asami H, Ito Y and Yoshida K: Overexpression of RhoA, Rac1, and CDC42 GTPases is associated with progression in testicular cancer. Clin Cancer Res. 10:4799–4805. 2004. View Article : Google Scholar : PubMed/NCBI
32	Horiuchi A, Imai T, Wang C, Ohira S, Feng Y, Nikaido T and Konishi I: Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest. 83:861–870. 2003. View Article : Google Scholar : PubMed/NCBI
33	Zhao XQ and Lu X: Expression of RhoA and ROCK in breast carcinomas and their significance. J Radioimmunol. 4:439–442. 2012.
34	Wang X, Jiang W, Kang J, Liu Q and Nie M: Knockdown of RhoA expression alters ovarian cancer biological behavior in vitro and in nude mice. Oncol Rep. 34:891–899. 2015.PubMed/NCBI
35	Slack JL, Bi W, Livak KJ, Beaubier N, Yu M, Clark M, Kim SH, Gallagher RE and Willman CL: Pre-clinical validation of a novel, highly sensitive assay to detect PML-RARalpha mRNA using real-time reverse-transcription polymerase chain reaction. J Mol Diagn. 3:141–149. 2001. View Article : Google Scholar : PubMed/NCBI
36	Gu Y, Zhang J, Mi W, Yang J, Han F, Lu X and Yu W: Silencing of GM3 synthase suppresses lung metastasis of murine breast cancer cells. Breast Cancer Res. 10:R12008. View Article : Google Scholar : PubMed/NCBI
37	Yanagisawa M and Anastasiadis PZ: p120 catenin is essential for mesenchymal cadherin-mediated regulation of cell motility and invasiveness. J Cell Biol. 174:1087–1096. 2006. View Article : Google Scholar : PubMed/NCBI
38	Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M and Narumiya S: Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 389:990–994. 1997. View Article : Google Scholar : PubMed/NCBI
39	Uehata M: Y-27632. Selective probe of ROCK/Rho-kinase. JikkenIgaku. 17:850–855. 1999.
40	Magtibay PM, Adams PB, Silverman MB, Cha SS and Podratz KC: Splenectomy as part of cytoreductive surgery in ovarian cancer. Gynecol Oncol. 102:369–374. 2006. View Article : Google Scholar : PubMed/NCBI
41	Lim MC, Kang S, Lee KS, Han SS, Park SJ, Seo SS and Park SY: The clinical significance of hepatic parenchymal metastasis in patients with primary epithelial ovarian cancer. Gynecol Oncol. 112:28–34. 2009. View Article : Google Scholar : PubMed/NCBI
42	Braun S, Schindlbeck C, Hepp F, Janni W, Kentenich C, Riethmüller G and Pantel K: Occult tumor cells in bone marrow of patients with locoregionally restricted ovarian cancer predict early distant metastatic relapse. J ClinOncol. 19:368–375. 2001. View Article : Google Scholar
43	Schmidt LJ, Duncan K, Yadav N, Regan KM, Verone AR, Lohse CM, Pop EA, Attwood K, Wilding G, Mohler JL, et al: RhoA as a mediator of clinically relevant androgen action in prostate cancer cells. Mol Endocrinol. 26:716–735. 2012. View Article : Google Scholar : PubMed/NCBI
44	Zohrabian VM, Forzani B, Chau Z, Murali R and Jhanwar-Uniyal M: Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation. Anticancer Res. 29:119–123. 2009.PubMed/NCBI
45	Somlyo AV, Bradshaw D, Ramos S, Murphy C, Myers CE and Somlyo AP: Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem Biophys Res Commun. 269:652–659. 2000. View Article : Google Scholar : PubMed/NCBI
46	Ying H, Biroc SL, Li WW, Alicke B, Xuan JA, Pagila R, Ohashi Y, Okada T, Kamata Y and Dinter H: The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Ther. 5:2158–2164. 2006. View Article : Google Scholar : PubMed/NCBI
47	Nakajima M, Katayama K, Tamechika I, Hayashi K, Amano Y, Uehata M and Kondo T: WF-536 inhibits metastatic invasion by enhancing the host cell barrier and inhibiting tumour cell motility. Clin Exp Pharmacol Physiol. 30:457–463. 2003. View Article : Google Scholar : PubMed/NCBI
48	Wong CC, Wong CM, Tung EK, Man K and Ng IO: Rho-kinase 2 is frequently overexpressed in hepatocellular carcinoma and involved in tumor invasion. Hepatology. 49:1583–1594. 2009. View Article : Google Scholar : PubMed/NCBI
49	Nakajima M, Hayashi K, Egi Y, Katayama K, Amano Y, Uehata M, Ohtsuki M, Fujii A, Oshita K and Kataoka H: Effect of Wf-536, a novel ROCK inhibitor, against metastasis of B16 melanoma. Cancer Chemother Pharmacol. 52:319–324. 2003. View Article : Google Scholar : PubMed/NCBI
50	Sahai E, Ishizaki T, Narumiya S and Treisman R: Transformation mediated by RhoA requires activity of ROCK kinases. Curr Biol. 9:136–145. 1999. View Article : Google Scholar : PubMed/NCBI
51	Xue F, Takahara T, Yata Y, Xia Q, Nonome K, Shinno E, Kanayama M, Takahara S and Sugiyama T: Blockade of Rho/Rho-associated coiled coil-forming kinase signaling can prevent progression of hepatocellular carcinoma in matrix metalloproteinase-dependent manner. Hepatol Res. 38:810–817. 2006. View Article : Google Scholar
52	Larrea MD, Wander SA and Slingerland JM: p27 as Jekyll and Hyde: Regulation of cell cycle and cell motility. Cell Cycle. 8:3455–3461. 2009. View Article : Google Scholar : PubMed/NCBI
53	Hoshino D, Tomari T, Nagano M, Koshikawa N and Seiki M: A novel protein associated with membrane-type 1 matrix metalloproteinase binds p27(kip1) and regulates RhoA activation, actin remodeling and matrigel invasion. J Biol Chem. 284:27315–27326. 2009. View Article : Google Scholar : PubMed/NCBI
54	Chang YC, Nalbant P, Birkenfeld J, Chang ZF and Bokoch GM: GEF-H1 couples nocodazole-induced microtubule disassembly to cell contractility via RhoA. Mol Biol Cell. 19:2147–2153. 2008. View Article : Google Scholar : PubMed/NCBI